<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00369824</url>
  </required_header>
  <id_info>
    <org_study_id>107682</org_study_id>
    <nct_id>NCT00369824</nct_id>
  </id_info>
  <brief_title>Evaluation of Safety and Immunogenicity of Co-administering HPV Vaccine With Other Vaccines in Healthy Female Subjects</brief_title>
  <official_title>A Randomized, Open Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' HPV Vaccine Co-administered Intramuscularly With Boostrix® and/or Menactra™ in Healthy Female Subjects Aged 11-18 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      Infection with human papillomavirus (HPV) has been clearly established as the central cause
      of cervical cancer. Vaccination of pre-teens and adolescents, ideally before sexual debut and
      thus before exposure to oncogenic HPV, is a rational strategy for prevention of cervical
      cancer, and so HPV vaccination could complement the existing pre-adolescent/adolescents
      platform. Therefore, this Phase 3b study is designed to evaluate the safety and
      immunogenicity of co-administering Boostrix and/or Menactra with GSK Biologicals' HPV vaccine
      (580299) as compared to the administration of any of the vaccines alone.

      The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep
      2007.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With Anti-diphtheria Toxoid (Anti-D) and Anti-tetanus Toxoid (Anti-T) Antibody Concentrations Above 1.0 International Unit Per Milliliter (IU/mL)</measure>
    <time_frame>Before and one month after vaccination with Boostrix</time_frame>
    <description>Anti-D and anti-T antibodies cut-off values assessed include 1.0 international unit per milliliter (IU/mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of Anti-pertussis Toxoid (Anti-PT), Anti-pertactin (Anti-PRN) and Anti-filamentous Hemagglutinin (Anti-FHA) Antibodies</measure>
    <time_frame>Before and one month after vaccination with Boostrix</time_frame>
    <description>Concentrations given as Geometric Means Concentrations (GMCs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Titer of Meningococcal Serogroup A (Anti-A), Meningococcal Serogroup C (Anti-C), Meningococcal Serogroup Y (Anti-Y) and Meningococcal Serogroup W-135 (Anti-W135) Antibodies</measure>
    <time_frame>Before and one month after vaccination with Menactra</time_frame>
    <description>Titers given as Geometric Mean Titers (GMTs)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Anti-human Papilloma Virus 16 (Anti-HPV16) and Anti-human Papilloma Virus 18 (Anti-HPV18) Antibody Concentrations Above Pre-defined Cut-off Values</measure>
    <time_frame>Before vaccination (PRE), one month post Dose 2 (Mth2) and one and six months post Dose 3 (Mth 7 and Mth 12)</time_frame>
    <description>Cut-off values assessed include 8 enzyme-linked immunosorbent assay units Per Milliliter (EL.U/mL) for anti-HPV16 antibodies and 7 EL.U/mL for anti-HPV18 antibodies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Anti-diphtheria Toxoid (Anti-D) and Anti-tetanus Toxoid (Anti-T) Antibody Concentrations Above 0.1 International Unit Per Milliliter (IU/mL)</measure>
    <time_frame>Before and one month after vaccination with Boostrix</time_frame>
    <description>Anti-D and anti-T antibodies cut-off values assessed include 0.1 international unit per milliliter (IU/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of Anti-D and Anti-T Antibodies</measure>
    <time_frame>Before and one month after vaccination with Boostrix</time_frame>
    <description>Concentrations given as Geometric Mean Concentrations (GMCs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Booster Response for Anti-D and Anti-T</measure>
    <time_frame>One month after vaccination with Boostrix</time_frame>
    <description>Booster responses for anti-D and anti-T defined as:
For initially seronegative subjects (pre-vaccination titer below cut-off: &lt; 0.1 IU/mL): antibody titer at least 4 times the cut-off (post-vaccination titer ≥ 0.4 IU/mL)
For initially seropositive subjects (pre-vaccination titer above 0.1 IU/mL): an increase in antibody titer of at least 4 times the pre-vaccination titer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Booster Response for Anti-PT, Anti-FHA and Anti-PRN</measure>
    <time_frame>One month after vaccination with Boostrix</time_frame>
    <description>Booster responses defined as:
For initially seronegative subjects (pre-vaccination titer below cut-off: &lt; 5 EL.U/mL): antibody titers at least 4 times the cut-off,
For initially seropositive subjects with pre-vaccination titer above 5 EL.U/mL and &lt; 20 EL.U/mL: an increase in antibody titers of at least 4 times the pre-vaccination titer,
For initially seropositive subjects with pre-vaccination titer ≥ 20 EL.U/mL: an increase in antibody titers of at least two times the pre-vaccination titer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Anti-A, Anti-C, Anti-Y and Anti-W135 Vaccine Response</measure>
    <time_frame>One month after vaccination with Menactra</time_frame>
    <description>Vaccine responses for anti-A, C, Y and W-135 defined as:
For initially seronegative subjects (pre-vaccination titer below cut-off of 8): antibody titers at least 4 times the cut-off (post vaccination titer ≥ 32)
For initially seropositive subjects (pre-vaccination titer above 8): antibody titers at least 4 times the pre-vaccination antibody titer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Solicited Local Symptoms</measure>
    <time_frame>During the 7-day period following each vaccination</time_frame>
    <description>Solicited local symptoms assessed include pain, redness and swelling.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Solicited General Symptoms</measure>
    <time_frame>During the 7-day period following each vaccination</time_frame>
    <description>Solicited general symptoms assessed include Arthralgia, fatigue, fever, gastrointestinal, headache, myalgia, rash and urticaria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Unsolicited Adverse Events (AEs)</measure>
    <time_frame>During the 30-day period following each vaccination</time_frame>
    <description>Unsolicited adverse event = Any adverse event (AE) reported in addition to those solicited during the clinical study. Also any &quot;solicited&quot; symptom with onset outside the specified period of follow-up for solicited symptoms was reported as an unsolicited adverse event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Serious Adverse Events</measure>
    <time_frame>During the active phase of the study (up to Month 7 or Month 8) and throughout the entire study (up to Month 12 or Month 13)</time_frame>
    <description>Serious adverse events assessed include medical occurrences that results in death, is life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Unsolicited Adverse Events as New Onset Chronic Diseases (NOCDs)</measure>
    <time_frame>During the active phase of the study (up to Month 7 or Month 8) and throughout the entire study period (up to Month 12 or Month 13)</time_frame>
    <description>NOCDs assessed include e.g. autoimmune disorders, asthma, type I diabetes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Medically Significant Adverse Events (AEs)</measure>
    <time_frame>During the active phase (up to Month 7 or Month 8) and throughout the entire study (up to Month 12 or Month 13)</time_frame>
    <description>Medically significant AEs assessed include AEs prompting emergency room or physician visits that are not related to common diseases or SAEs that are not related to common diseases.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">1330</enrollment>
  <condition>Infections, Papillomavirus</condition>
  <arm_group>
    <arm_group_label>Cervarix + Boostrix/Menactra Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received Cervarix and Boostrix at Month 0, Menactra and Cervarix at Month 1 and Cervarix alone at Month 6.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cervarix + Menactra/Boostrix Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received Menactra and Cervarix at Month 0, Boostrix and Cervarix at Month 1 and Cervarix alone at Month 6.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cervarix + Boostrix + Menactra Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received Boostrix, Menactra and Cervarix at Month 0 and Cervarix alone at Months 1 and 6.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Boostrix/Cervarix Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received Boostrix at Month 0 and Cervarix at Months 1, 2 and 7.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Menactra/Cervarix Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received Menactra at Month 0 and Cervarix at Months 1, 2 and 7.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cervarix Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received Cervarix at Months 0, 1 and 6.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Different formulations of GSK Biologicals' HPV vaccine (580299)</intervention_name>
    <description>Three doses of vaccine administered intramuscularly, with the second and third dose given one month and six months after the first dose respectively</description>
    <arm_group_label>Cervarix + Boostrix + Menactra Group</arm_group_label>
    <arm_group_label>Cervarix Group</arm_group_label>
    <arm_group_label>Cervarix + Menactra/Boostrix Group</arm_group_label>
    <arm_group_label>Boostrix/Cervarix Group</arm_group_label>
    <arm_group_label>Menactra/Cervarix Group</arm_group_label>
    <arm_group_label>Cervarix + Boostrix/Menactra Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Menactra TM</intervention_name>
    <description>One dose of vaccine administered intramuscularly</description>
    <arm_group_label>Cervarix + Boostrix + Menactra Group</arm_group_label>
    <arm_group_label>Cervarix + Menactra/Boostrix Group</arm_group_label>
    <arm_group_label>Boostrix/Cervarix Group</arm_group_label>
    <arm_group_label>Menactra/Cervarix Group</arm_group_label>
    <arm_group_label>Cervarix + Boostrix/Menactra Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Boostrix TM</intervention_name>
    <description>One dose of vaccine administered intramuscularly</description>
    <arm_group_label>Cervarix + Boostrix + Menactra Group</arm_group_label>
    <arm_group_label>Cervarix + Menactra/Boostrix Group</arm_group_label>
    <arm_group_label>Boostrix/Cervarix Group</arm_group_label>
    <arm_group_label>Cervarix + Boostrix/Menactra Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who the investigator believes that they can, and will, comply with the
             requirements of the protocol should be enrolled in the study.

          -  A female between, and including, 11 and 18 years of age at the time of the first
             vaccination.

          -  Written informed consent obtained from parents/legally acceptable representative of
             the subject and written informed assent obtained from the subject if the subject is
             less than 18 years of age, or written informed consent obtained from the subject if
             the subject is 18 years of age.

          -  Healthy subjects, as established by medical history and history-directed physical
             examination, before entering into the study.

          -  Previously completed routine childhood vaccinations against diphtheria, tetanus and
             pertussis diseases, according to the recommended vaccination schedule at the time.

          -  Subjects must have a negative urine pregnancy test.

          -  Subjects of childbearing potential at the time of study entry are required to be
             abstinent or use adequate contraceptive precautions for 30 days prior to vaccination.
             Subjects also are required to agree to continue such precautions for two months after
             completion of the vaccination series. Female subjects who reach menarche (began
             menstruating) during the study and therefore become of child-bearing potential are
             required to agree to follow the same precautions.

        Exclusion Criteria:

          -  Use of any investigational or non-registered product other than the study vaccine
             within 30 days preceding the first dose of study vaccine, or planned use during the
             study period.

          -  Concurrently participating in another clinical study, at any time during the study
             period (up to the Month 12/13 visit), in which the subject has been or will be exposed
             to an investigational or a non-investigational product.

          -  Chronic administration of immunosuppressants or other immune-modifying drugs within
             six months prior to the first vaccine dose.

          -  Planned administration/administration of a vaccine not foreseen by the study protocol
             within 30 days before and 30 days after each dose of vaccine. Administration of
             routine vaccines up to 8 days before the first dose of study vaccine is allowed.
             Enrolment will be deferred until the subject is outside of specified window.

          -  A woman planning to become pregnant, likely to become pregnant or planning to
             discontinue contraceptive precautions during the study period and up to two months
             after the last vaccine dose.

          -  Pregnant or breastfeeding women.

          -  Previous vaccination against HPV, or planned administration of any HPV vaccine other
             than that foreseen by the study protocol during the study period.

          -  previous administration of components of the investigational vaccine

          -  Administration of a pre-school booster of diphtheria, tetanus, pertussis vaccine
             within the previous five years.

          -  Administration of a diphtheria-tetanus booster or tetanus-diphteria-acellular
             pertussis (Tdap) vaccine within the previous five years.

          -  Previous vaccination against Neisseria meningitidis.

          -  Hypersensitivity to latex.

          -  Cancer or autoimmune disease under treatment.

          -  History of allergic disease or reactions likely to be exacerbated by any component of
             the vaccine or following any other tetanus toxoid, diphtheria toxoid or
             pertussis-containing vaccine.

          -  History of encephalopathy within seven days of administration of a previous dose of
             pertussis vaccine that is not attributable to another identifiable cause.

          -  Progressive neurologic disorder, uncontrolled epilepsy or progressive encephalopathy.

          -  Temperature of &gt;= 105°F within 48 hours of receipt of a prior dose of diphteria-
             tetanu-pertussis (DTP) vaccine, not due to another identifiable cause.

          -  Collapse or shock-like state within 48 hours of receipt of a prior dose of DTP
             vaccine.

          -  Seizures with or without fever within three days of a prior dose of DTP vaccine.

          -  Severe Arthus-type hypersensitivity reactions following a prior dose of tetanus toxoid
             within the previous 10 years.

          -  Previous history of Guillain-Barré syndrome.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition

          -  Acute disease at the time of enrolment. All vaccines can be administered to persons
             with a minor illness

          -  Administration of immunoglobulins and/or any blood products within the 3 months
             preceding the first dose of study vaccine or planned administration during the study
             period.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>11 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madera</city>
        <state>California</state>
        <zip>93637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rolling Hills Estates</city>
        <state>California</state>
        <zip>90274</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Centennial</city>
        <state>Colorado</state>
        <zip>80112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Golden</city>
        <state>Colorado</state>
        <zip>80401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Thornton</city>
        <state>Colorado</state>
        <zip>80233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cocoa Beach</city>
        <state>Florida</state>
        <zip>32931</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Arkansas City</city>
        <state>Kansas</state>
        <zip>67005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bardstown</city>
        <state>Kentucky</state>
        <zip>40004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bossier City</city>
        <state>Louisiana</state>
        <zip>71111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Milford</city>
        <state>Massachusetts</state>
        <zip>01757</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Niles</city>
        <state>Michigan</state>
        <zip>49120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stevensville</city>
        <state>Michigan</state>
        <zip>49127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Edison</city>
        <state>New Jersey</state>
        <zip>08817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Whitehouse Station</city>
        <state>New Jersey</state>
        <zip>08889</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cary</city>
        <state>North Carolina</state>
        <zip>27518</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Laurinburg</city>
        <state>North Carolina</state>
        <zip>28352</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sylva</city>
        <state>North Carolina</state>
        <zip>28779</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Boardman</city>
        <state>Ohio</state>
        <zip>44512</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <zip>16501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Greenville</city>
        <state>Pennsylvania</state>
        <zip>16125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Uniontown</city>
        <state>Pennsylvania</state>
        <zip>15401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gray</city>
        <state>Tennessee</state>
        <zip>37615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Angelo</city>
        <state>Texas</state>
        <zip>76904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Burke</city>
        <state>Virginia</state>
        <zip>22015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vienna</city>
        <state>Virginia</state>
        <zip>22180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 28, 2006</study_first_submitted>
  <study_first_submitted_qc>August 28, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2006</study_first_posted>
  <results_first_submitted>September 3, 2009</results_first_submitted>
  <results_first_submitted_qc>September 3, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 8, 2009</results_first_posted>
  <last_update_submitted>November 3, 2016</last_update_submitted>
  <last_update_submitted_qc>November 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HPV</keyword>
  <keyword>HPV, diptheria, pertussis, tetanus, meningitis</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>107682</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>107682</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>107682</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>107682</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>107682</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>107682</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cervarix + Boostrix/Menactra Group</title>
          <description>Subjects received Cervarix and Boostrix at Month 0, Menactra and Cervarix at Month 1 and Cervarix alone at Month 6.</description>
        </group>
        <group group_id="P2">
          <title>Cervarix + Menactra/Boostrix Group</title>
          <description>Subjects received Menactra and Cervarix at Month 0, Boostrix and Cervarix at Month 1 and Cervarix alone at Month 6.</description>
        </group>
        <group group_id="P3">
          <title>Cervarix + Boostrix + Menactra Group</title>
          <description>Subjects received Boostrix, Menactra and Cervarix at Month 0 and Cervarix alone at Months 1 and 6.</description>
        </group>
        <group group_id="P4">
          <title>Boostrix/Cervarix Group</title>
          <description>Subjects received Boostrix at Month 0 and Cervarix at Months 1, 2 and 7.</description>
        </group>
        <group group_id="P5">
          <title>Menactra/Cervarix Group</title>
          <description>Subjects received Menactra at Month 0 and Cervarix at Months 1, 2 and 7.</description>
        </group>
        <group group_id="P6">
          <title>Cervarix Group</title>
          <description>Subjects received Cervarix at Months 0, 1 and 6.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="212"/>
                <participants group_id="P2" count="214"/>
                <participants group_id="P3" count="214"/>
                <participants group_id="P4" count="214"/>
                <participants group_id="P5" count="214"/>
                <participants group_id="P6" count="215"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="197"/>
                <participants group_id="P2" count="195"/>
                <participants group_id="P3" count="202"/>
                <participants group_id="P4" count="199"/>
                <participants group_id="P5" count="196"/>
                <participants group_id="P6" count="204"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="15"/>
                <participants group_id="P5" count="18"/>
                <participants group_id="P6" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cervarix + Boostrix/Menactra Group</title>
          <description>Subjects received Cervarix and Boostrix at Month 0, Menactra and Cervarix at Month 1 and Cervarix alone at Month 6.</description>
        </group>
        <group group_id="B2">
          <title>Cervarix + Menactra/Boostrix Group</title>
          <description>Subjects received Menactra and Cervarix at Month 0, Boostrix and Cervarix at Month 1 and Cervarix alone at Month 6.</description>
        </group>
        <group group_id="B3">
          <title>Cervarix + Boostrix + Menactra Group</title>
          <description>Subjects received Boostrix, Menactra and Cervarix at Month 0 and Cervarix alone at Months 1 and 6.</description>
        </group>
        <group group_id="B4">
          <title>Boostrix/Cervarix Group</title>
          <description>Subjects received Boostrix at Month 0 and Cervarix at Months 1, 2 and 7.</description>
        </group>
        <group group_id="B5">
          <title>Menactra/Cervarix Group</title>
          <description>Subjects received Menactra at Month 0 and Cervarix at Months 1, 2 and 7.</description>
        </group>
        <group group_id="B6">
          <title>Cervarix Group</title>
          <description>Subjects received Cervarix at Months 0, 1 and 6.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="212"/>
            <count group_id="B2" value="214"/>
            <count group_id="B3" value="214"/>
            <count group_id="B4" value="214"/>
            <count group_id="B5" value="214"/>
            <count group_id="B6" value="215"/>
            <count group_id="B7" value="1283"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.5" spread="2.27"/>
                    <measurement group_id="B2" value="13.3" spread="2.28"/>
                    <measurement group_id="B3" value="13.5" spread="2.26"/>
                    <measurement group_id="B4" value="13.5" spread="2.33"/>
                    <measurement group_id="B5" value="13.3" spread="2.35"/>
                    <measurement group_id="B6" value="13.4" spread="2.34"/>
                    <measurement group_id="B7" value="13.4" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="212"/>
                    <measurement group_id="B2" value="214"/>
                    <measurement group_id="B3" value="214"/>
                    <measurement group_id="B4" value="214"/>
                    <measurement group_id="B5" value="214"/>
                    <measurement group_id="B6" value="215"/>
                    <measurement group_id="B7" value="1283"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Anti-diphtheria Toxoid (Anti-D) and Anti-tetanus Toxoid (Anti-T) Antibody Concentrations Above 1.0 International Unit Per Milliliter (IU/mL)</title>
        <description>Anti-D and anti-T antibodies cut-off values assessed include 1.0 international unit per milliliter (IU/mL)</description>
        <time_frame>Before and one month after vaccination with Boostrix</time_frame>
        <population>Analysis was performed on the According-to-Protocol (ATP) cohort for analysis of immunogenicity, Month 1 and only for Cervarix + Boostrix/Menactra, Cervarix + Boostrix + Menactra and Boostrix/Cervarix groups.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix + Boostrix/Menactra Group</title>
            <description>Subjects received Cervarix and Boostrix at Month 0, Menactra and Cervarix at Month 1 and Cervarix alone at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix + Menactra/Boostrix Group</title>
            <description>Subjects received Menactra and Cervarix at Month 0, Boostrix and Cervarix at Month 1 and Cervarix alone at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Cervarix + Boostrix + Menactra Group</title>
            <description>Subjects received Boostrix, Menactra and Cervarix at Month 0 and Cervarix alone at Months 1 and 6.</description>
          </group>
          <group group_id="O4">
            <title>Boostrix/Cervarix Group</title>
            <description>Subjects received Boostrix at Month 0 and Cervarix at Months 1, 2 and 7.</description>
          </group>
          <group group_id="O5">
            <title>Menactra/Cervarix Group</title>
            <description>Subjects received Menactra at Month 0 and Cervarix at Months 1, 2 and 7.</description>
          </group>
          <group group_id="O6">
            <title>Cervarix Group</title>
            <description>Subjects received Cervarix at Months 0, 1 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Anti-diphtheria Toxoid (Anti-D) and Anti-tetanus Toxoid (Anti-T) Antibody Concentrations Above 1.0 International Unit Per Milliliter (IU/mL)</title>
          <description>Anti-D and anti-T antibodies cut-off values assessed include 1.0 international unit per milliliter (IU/mL)</description>
          <population>Analysis was performed on the According-to-Protocol (ATP) cohort for analysis of immunogenicity, Month 1 and only for Cervarix + Boostrix/Menactra, Cervarix + Boostrix + Menactra and Boostrix/Cervarix groups.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="201"/>
                <count group_id="O4" value="199"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-D (Before vaccination) (n=193,199,199)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O3" value="33"/>
                    <measurement group_id="O4" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-D (1 month after vaccination) (n=194,201,199)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="193"/>
                    <measurement group_id="O3" value="200"/>
                    <measurement group_id="O4" value="190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-T (Before vaccination) (n=194,199,199)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O3" value="75"/>
                    <measurement group_id="O4" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-T (1 month after vaccination) (n=194,201,199)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="194"/>
                    <measurement group_id="O3" value="201"/>
                    <measurement group_id="O4" value="198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Concentration of Anti-pertussis Toxoid (Anti-PT), Anti-pertactin (Anti-PRN) and Anti-filamentous Hemagglutinin (Anti-FHA) Antibodies</title>
        <description>Concentrations given as Geometric Means Concentrations (GMCs)</description>
        <time_frame>Before and one month after vaccination with Boostrix</time_frame>
        <population>Analysis was performed on the According-to-Protocol (ATP) cohort for analysis of immunogenicity Month 1, and only for Cervarix + Boostrix/Menactra, Cervarix + Boostrix + Menactra and Boostrix/Cervarix groups.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix + Boostrix/Menactra Group</title>
            <description>Subjects received Cervarix and Boostrix at Month 0, Menactra and Cervarix at Month 1 and Cervarix alone at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix + Menactra/Boostrix Group</title>
            <description>Subjects received Menactra and Cervarix at Month 0, Boostrix and Cervarix at Month 1 and Cervarix alone at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Cervarix + Boostrix + Menactra Group</title>
            <description>Subjects received Boostrix, Menactra and Cervarix at Month 0 and Cervarix alone at Months 1 and 6.</description>
          </group>
          <group group_id="O4">
            <title>Boostrix/Cervarix Group</title>
            <description>Subjects received Boostrix at Month 0 and Cervarix at Months 1, 2 and 7.</description>
          </group>
          <group group_id="O5">
            <title>Menactra/Cervarix Group</title>
            <description>Subjects received Menactra at Month 0 and Cervarix at Months 1, 2 and 7.</description>
          </group>
          <group group_id="O6">
            <title>Cervarix Group</title>
            <description>Subjects received Cervarix at Months 0, 1 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration of Anti-pertussis Toxoid (Anti-PT), Anti-pertactin (Anti-PRN) and Anti-filamentous Hemagglutinin (Anti-FHA) Antibodies</title>
          <description>Concentrations given as Geometric Means Concentrations (GMCs)</description>
          <population>Analysis was performed on the According-to-Protocol (ATP) cohort for analysis of immunogenicity Month 1, and only for Cervarix + Boostrix/Menactra, Cervarix + Boostrix + Menactra and Boostrix/Cervarix groups.</population>
          <units>International Units per Milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="201"/>
                <count group_id="O4" value="199"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-PT (Before vaccination) (n=194,196,198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.515" lower_limit="8.078" upper_limit="11.207"/>
                    <measurement group_id="O3" value="10.356" lower_limit="8.733" upper_limit="12.280"/>
                    <measurement group_id="O4" value="11.164" lower_limit="9.319" upper_limit="13.375"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PT (1month after vaccination) (n=194,201,199)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.682" lower_limit="66.001" upper_limit="84.504"/>
                    <measurement group_id="O3" value="70.908" lower_limit="61.763" upper_limit="81.408"/>
                    <measurement group_id="O4" value="78.807" lower_limit="69.035" upper_limit="89.962"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-FHA (Before vaccination) (n=192,195,196)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.472" lower_limit="27.019" upper_limit="39.026"/>
                    <measurement group_id="O3" value="37.671" lower_limit="31.572" upper_limit="44.947"/>
                    <measurement group_id="O4" value="38.819" lower_limit="32.467" upper_limit="46.413"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-FHA (1month after vaccination) (n=194,201,199</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="648.018" lower_limit="577.051" upper_limit="727.714"/>
                    <measurement group_id="O3" value="544.665" lower_limit="481.612" upper_limit="615.974"/>
                    <measurement group_id="O4" value="676.765" lower_limit="596.493" upper_limit="767.840"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PRN (Before vaccination) (n=193,199,199)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.978" lower_limit="10.781" upper_limit="15.622"/>
                    <measurement group_id="O3" value="16.040" lower_limit="13.479" upper_limit="19.087"/>
                    <measurement group_id="O4" value="15.871" lower_limit="13.033" upper_limit="19.327"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PRN(1month after vaccination) (n=194,199,198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="416.049" lower_limit="345.557" upper_limit="500.921"/>
                    <measurement group_id="O3" value="323.205" lower_limit="268.389" upper_limit="389.217"/>
                    <measurement group_id="O4" value="379.467" lower_limit="311.050" upper_limit="462.933"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Titer of Meningococcal Serogroup A (Anti-A), Meningococcal Serogroup C (Anti-C), Meningococcal Serogroup Y (Anti-Y) and Meningococcal Serogroup W-135 (Anti-W135) Antibodies</title>
        <description>Titers given as Geometric Mean Titers (GMTs)</description>
        <time_frame>Before and one month after vaccination with Menactra</time_frame>
        <population>Analysis was performed on the According to Protocol (ATP) cohort for immunogenicity Month1 and only for Cervarix + Menactra/Boostrix, Cervarix + Boostrix + Menactra and Menactra/Cervarix groups.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix + Boostrix/Menactra Group</title>
            <description>Subjects received Cervarix and Boostrix at Month 0, Menactra and Cervarix at Month 1 and Cervarix alone at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix + Menactra/Boostrix Group</title>
            <description>Subjects received Menactra and Cervarix at Month 0, Boostrix and Cervarix at Month 1 and Cervarix alone at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Cervarix + Boostrix + Menactra Group</title>
            <description>Subjects received Boostrix, Menactra and Cervarix at Month 0 and Cervarix alone at Months 1 and 6.</description>
          </group>
          <group group_id="O4">
            <title>Boostrix/Cervarix Group</title>
            <description>Subjects received Boostrix at Month 0 and Cervarix at Months 1, 2 and 7.</description>
          </group>
          <group group_id="O5">
            <title>Menactra/Cervarix Group</title>
            <description>Subjects received Menactra at Month 0 and Cervarix at Months 1, 2 and 7.</description>
          </group>
          <group group_id="O6">
            <title>Cervarix Group</title>
            <description>Subjects received Cervarix at Months 0, 1 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Titer of Meningococcal Serogroup A (Anti-A), Meningococcal Serogroup C (Anti-C), Meningococcal Serogroup Y (Anti-Y) and Meningococcal Serogroup W-135 (Anti-W135) Antibodies</title>
          <description>Titers given as Geometric Mean Titers (GMTs)</description>
          <population>Analysis was performed on the According to Protocol (ATP) cohort for immunogenicity Month1 and only for Cervarix + Menactra/Boostrix, Cervarix + Boostrix + Menactra and Menactra/Cervarix groups.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="200"/>
                <count group_id="O3" value="200"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="203"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-A (Before vaccination) (n=180,179,184)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="898.650" lower_limit="780.476" upper_limit="1034.717"/>
                    <measurement group_id="O3" value="829.508" lower_limit="716.806" upper_limit="959.931"/>
                    <measurement group_id="O5" value="763.324" lower_limit="648.325" upper_limit="898.721"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-A (1month after vaccination) (n=190,181,184)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="7570.228" lower_limit="6701.054" upper_limit="8556.140"/>
                    <measurement group_id="O3" value="6919.419" lower_limit="6197.308" upper_limit="7725.670"/>
                    <measurement group_id="O5" value="8352.685" lower_limit="7435.325" upper_limit="9383.226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-C (Before vaccination) (n=184,190,182)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="37.738" lower_limit="27.249" upper_limit="52.264"/>
                    <measurement group_id="O3" value="35.827" lower_limit="26.004" upper_limit="49.360"/>
                    <measurement group_id="O5" value="30.696" lower_limit="21.974" upper_limit="42.879"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-C (1month after vaccination) (n=200,200,203)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="2497.463" lower_limit="1985.199" upper_limit="3141.912"/>
                    <measurement group_id="O3" value="2112.366" lower_limit="1708.155" upper_limit="2612.228"/>
                    <measurement group_id="O5" value="2375.963" lower_limit="1938.868" upper_limit="2911.595"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Y (Before vaccination) (n=183,189,192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="87.356" lower_limit="63.239" upper_limit="120.670"/>
                    <measurement group_id="O3" value="72.756" lower_limit="52.881" upper_limit="100.101"/>
                    <measurement group_id="O5" value="110.911" lower_limit="81.291" upper_limit="151.322"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Y (1month after vaccination) (n=200,200,203)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="4787.556" lower_limit="4079.870" upper_limit="5617.996"/>
                    <measurement group_id="O3" value="3947.330" lower_limit="3292.007" upper_limit="4733.105"/>
                    <measurement group_id="O5" value="4335.380" lower_limit="3688.566" upper_limit="5095.617"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-W135 (Before vaccination) (n=185,188,189)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="33.946" lower_limit="24.902" upper_limit="46.274"/>
                    <measurement group_id="O3" value="28.750" lower_limit="21.338" upper_limit="38.737"/>
                    <measurement group_id="O5" value="34.206" lower_limit="25.374" upper_limit="46.111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-W135(1month after vaccination)(n=200,200,201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="4564.037" lower_limit="3990.523" upper_limit="5219.977"/>
                    <measurement group_id="O3" value="3856.584" lower_limit="3298.787" upper_limit="4508.700"/>
                    <measurement group_id="O5" value="5056.182" lower_limit="4401.292" upper_limit="5808.516"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Anti-human Papilloma Virus 16 (Anti-HPV16) and Anti-human Papilloma Virus 18 (Anti-HPV18) Antibody Concentrations Above Pre-defined Cut-off Values</title>
        <description>Cut-off values assessed include 8 enzyme-linked immunosorbent assay units Per Milliliter (EL.U/mL) for anti-HPV16 antibodies and 7 EL.U/mL for anti-HPV18 antibodies.</description>
        <time_frame>Before vaccination (PRE), one month post Dose 2 (Mth2) and one and six months post Dose 3 (Mth 7 and Mth 12)</time_frame>
        <population>Analysis was performed on the According to Protocol (ATP) cohort for immunogenicity at Month 12/13</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix + Boostrix/Menactra Group</title>
            <description>Subjects received Cervarix and Boostrix at Month 0, Menactra and Cervarix at Month 1 and Cervarix alone at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix + Menactra/Boostrix Group</title>
            <description>Subjects received Menactra and Cervarix at Month 0, Boostrix and Cervarix at Month 1 and Cervarix alone at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Cervarix + Boostrix + Menactra Group</title>
            <description>Subjects received Boostrix, Menactra and Cervarix at Month 0 and Cervarix alone at Months 1 and 6.</description>
          </group>
          <group group_id="O4">
            <title>Boostrix/Cervarix Group</title>
            <description>Subjects received Boostrix at Month 0 and Cervarix at Months 1, 2 and 7.</description>
          </group>
          <group group_id="O5">
            <title>Menactra/Cervarix Group</title>
            <description>Subjects received Menactra at Month 0 and Cervarix at Months 1, 2 and 7.</description>
          </group>
          <group group_id="O6">
            <title>Cervarix Group</title>
            <description>Subjects received Cervarix at Months 0, 1 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Anti-human Papilloma Virus 16 (Anti-HPV16) and Anti-human Papilloma Virus 18 (Anti-HPV18) Antibody Concentrations Above Pre-defined Cut-off Values</title>
          <description>Cut-off values assessed include 8 enzyme-linked immunosorbent assay units Per Milliliter (EL.U/mL) for anti-HPV16 antibodies and 7 EL.U/mL for anti-HPV18 antibodies.</description>
          <population>Analysis was performed on the According to Protocol (ATP) cohort for immunogenicity at Month 12/13</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="158"/>
                <count group_id="O3" value="165"/>
                <count group_id="O4" value="156"/>
                <count group_id="O5" value="147"/>
                <count group_id="O6" value="166"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-HPV16 PRE (n=163, 158, 164, 156, 146, 166)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV16 Mth2 (n= 163, 158, 163, 156, 145, 166)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163"/>
                    <measurement group_id="O2" value="158"/>
                    <measurement group_id="O3" value="163"/>
                    <measurement group_id="O4" value="156"/>
                    <measurement group_id="O5" value="145"/>
                    <measurement group_id="O6" value="166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV16 Mth7 (n=161, 158, 164, 156, 142, 164)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161"/>
                    <measurement group_id="O2" value="158"/>
                    <measurement group_id="O3" value="164"/>
                    <measurement group_id="O4" value="156"/>
                    <measurement group_id="O5" value="142"/>
                    <measurement group_id="O6" value="164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV16 Mth12 (n= 163, 158, 164, 156, 146, 166)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163"/>
                    <measurement group_id="O2" value="158"/>
                    <measurement group_id="O3" value="164"/>
                    <measurement group_id="O4" value="156"/>
                    <measurement group_id="O5" value="146"/>
                    <measurement group_id="O6" value="166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV18 PRE (n= 163, 157, 165, 152, 147, 165)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV18 Mth2 (n= 163, 157, 164, 152, 146, 165)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163"/>
                    <measurement group_id="O2" value="157"/>
                    <measurement group_id="O3" value="164"/>
                    <measurement group_id="O4" value="152"/>
                    <measurement group_id="O5" value="146"/>
                    <measurement group_id="O6" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV18 Mth7 (n= 161, 157, 165, 152, 143, 163)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161"/>
                    <measurement group_id="O2" value="157"/>
                    <measurement group_id="O3" value="165"/>
                    <measurement group_id="O4" value="152"/>
                    <measurement group_id="O5" value="143"/>
                    <measurement group_id="O6" value="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV18 Mth12 (n= 163, 157, 165, 152, 147, 165)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163"/>
                    <measurement group_id="O2" value="157"/>
                    <measurement group_id="O3" value="165"/>
                    <measurement group_id="O4" value="152"/>
                    <measurement group_id="O5" value="147"/>
                    <measurement group_id="O6" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Anti-diphtheria Toxoid (Anti-D) and Anti-tetanus Toxoid (Anti-T) Antibody Concentrations Above 0.1 International Unit Per Milliliter (IU/mL)</title>
        <description>Anti-D and anti-T antibodies cut-off values assessed include 0.1 international unit per milliliter (IU/mL)</description>
        <time_frame>Before and one month after vaccination with Boostrix</time_frame>
        <population>Analysis was performed on the According to Protocol (ATP) cohort for immunogenicity Month 1, and only for Cervarix + Boostrix/Menactra, Cervarix + Boostrix + Menactra and Boostrix/Cervarix groups</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix + Boostrix/Menactra Group</title>
            <description>Subjects received Cervarix and Boostrix at Month 0, Menactra and Cervarix at Month 1 and Cervarix alone at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix + Menactra/Boostrix Group</title>
            <description>Subjects received Menactra and Cervarix at Month 0, Boostrix and Cervarix at Month 1 and Cervarix alone at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Cervarix + Boostrix + Menactra Group</title>
            <description>Subjects received Boostrix, Menactra and Cervarix at Month 0 and Cervarix alone at Months 1 and 6.</description>
          </group>
          <group group_id="O4">
            <title>Boostrix/Cervarix Group</title>
            <description>Subjects received Boostrix at Month 0 and Cervarix at Months 1, 2 and 7.</description>
          </group>
          <group group_id="O5">
            <title>Menactra/Cervarix Group</title>
            <description>Subjects received Menactra at Month 0 and Cervarix at Months 1, 2 and 7.</description>
          </group>
          <group group_id="O6">
            <title>Cervarix Group</title>
            <description>Subjects received Cervarix at Months 0, 1 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Anti-diphtheria Toxoid (Anti-D) and Anti-tetanus Toxoid (Anti-T) Antibody Concentrations Above 0.1 International Unit Per Milliliter (IU/mL)</title>
          <description>Anti-D and anti-T antibodies cut-off values assessed include 0.1 international unit per milliliter (IU/mL)</description>
          <population>Analysis was performed on the According to Protocol (ATP) cohort for immunogenicity Month 1, and only for Cervarix + Boostrix/Menactra, Cervarix + Boostrix + Menactra and Boostrix/Cervarix groups</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="201"/>
                <count group_id="O4" value="199"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-D (Before vaccination) (n=193,199,199)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="170"/>
                    <measurement group_id="O3" value="181"/>
                    <measurement group_id="O4" value="167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-D (1month after vaccination) (n=194,201,199)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="194"/>
                    <measurement group_id="O3" value="201"/>
                    <measurement group_id="O4" value="199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-T (Before vaccination) (n=194,199,199)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="188"/>
                    <measurement group_id="O3" value="199"/>
                    <measurement group_id="O4" value="195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-T (1month after vaccination) (n=194,201,199)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="194"/>
                    <measurement group_id="O3" value="201"/>
                    <measurement group_id="O4" value="199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentration of Anti-D and Anti-T Antibodies</title>
        <description>Concentrations given as Geometric Mean Concentrations (GMCs)</description>
        <time_frame>Before and one month after vaccination with Boostrix</time_frame>
        <population>Analysis was performed on the According to Protocol (ATP) cohort for immunogenicity Month 1, and only for Cervarix + Boostrix/Menactra, Cervarix + Boostrix + Menactra and Boostrix/Cervarix groups.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix + Boostrix/Menactra Group</title>
            <description>Subjects received Cervarix and Boostrix at Month 0, Menactra and Cervarix at Month 1 and Cervarix alone at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix + Menactra/Boostrix Group</title>
            <description>Subjects received Menactra and Cervarix at Month 0, Boostrix and Cervarix at Month 1 and Cervarix alone at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Cervarix + Boostrix + Menactra Group</title>
            <description>Subjects received Boostrix, Menactra and Cervarix at Month 0 and Cervarix alone at Months 1 and 6.</description>
          </group>
          <group group_id="O4">
            <title>Boostrix/Cervarix Group</title>
            <description>Subjects received Boostrix at Month 0 and Cervarix at Months 1, 2 and 7.</description>
          </group>
          <group group_id="O5">
            <title>Menactra/Cervarix Group</title>
            <description>Subjects received Menactra at Month 0 and Cervarix at Months 1, 2 and 7.</description>
          </group>
          <group group_id="O6">
            <title>Cervarix Group</title>
            <description>Subjects received Cervarix at Months 0, 1 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration of Anti-D and Anti-T Antibodies</title>
          <description>Concentrations given as Geometric Mean Concentrations (GMCs)</description>
          <population>Analysis was performed on the According to Protocol (ATP) cohort for immunogenicity Month 1, and only for Cervarix + Boostrix/Menactra, Cervarix + Boostrix + Menactra and Boostrix/Cervarix groups.</population>
          <units>International Unit per Milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="201"/>
                <count group_id="O4" value="199"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-D (Before vaccination) (n=193,199,199)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.362" lower_limit="0.305" upper_limit="0.431"/>
                    <measurement group_id="O3" value="0.368" lower_limit="0.315" upper_limit="0.430"/>
                    <measurement group_id="O4" value="0.331" lower_limit="0.280" upper_limit="0.390"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-D (1month after vaccination) (n=194,201,199)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.928" lower_limit="7.821" upper_limit="10.192"/>
                    <measurement group_id="O3" value="27.438" lower_limit="24.297" upper_limit="30.984"/>
                    <measurement group_id="O4" value="7.527" lower_limit="6.492" upper_limit="8.727"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-T (Before vaccination) (n=194,199,199)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.811" lower_limit="0.686" upper_limit="0.960"/>
                    <measurement group_id="O3" value="0.895" lower_limit="0.765" upper_limit="1.046"/>
                    <measurement group_id="O4" value="0.700" lower_limit="0.602" upper_limit="0.814"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-T (1month after vaccination) (n=194,201,199)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.584" lower_limit="13.923" upper_limit="17.443"/>
                    <measurement group_id="O3" value="12.415" lower_limit="11.184" upper_limit="13.781"/>
                    <measurement group_id="O4" value="14.524" lower_limit="12.814" upper_limit="16.462"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Booster Response for Anti-D and Anti-T</title>
        <description>Booster responses for anti-D and anti-T defined as:
For initially seronegative subjects (pre-vaccination titer below cut-off: &lt; 0.1 IU/mL): antibody titer at least 4 times the cut-off (post-vaccination titer ≥ 0.4 IU/mL)
For initially seropositive subjects (pre-vaccination titer above 0.1 IU/mL): an increase in antibody titer of at least 4 times the pre-vaccination titer</description>
        <time_frame>One month after vaccination with Boostrix</time_frame>
        <population>Analysis was performed on the According to Protocol (ATP) cohort for immunogenicity Month 1, and only for Cervarix + Boostrix/Menactra, Cervarix + Boostrix + Menactra and Boostrix/Cervarix groups.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix + Boostrix/Menactra Group</title>
            <description>Subjects received Cervarix and Boostrix at Month 0, Menactra and Cervarix at Month 1 and Cervarix alone at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix + Menactra/Boostrix Group</title>
            <description>Subjects received Menactra and Cervarix at Month 0, Boostrix and Cervarix at Month 1 and Cervarix alone at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Cervarix + Boostrix + Menactra Group</title>
            <description>Subjects received Boostrix, Menactra and Cervarix at Month 0 and Cervarix alone at Months 1 and 6.</description>
          </group>
          <group group_id="O4">
            <title>Boostrix/Cervarix Group</title>
            <description>Subjects received Boostrix at Month 0 and Cervarix at Months 1, 2 and 7.</description>
          </group>
          <group group_id="O5">
            <title>Menactra/Cervarix Group</title>
            <description>Subjects received Menactra at Month 0 and Cervarix at Months 1, 2 and 7.</description>
          </group>
          <group group_id="O6">
            <title>Cervarix Group</title>
            <description>Subjects received Cervarix at Months 0, 1 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Booster Response for Anti-D and Anti-T</title>
          <description>Booster responses for anti-D and anti-T defined as:
For initially seronegative subjects (pre-vaccination titer below cut-off: &lt; 0.1 IU/mL): antibody titer at least 4 times the cut-off (post-vaccination titer ≥ 0.4 IU/mL)
For initially seropositive subjects (pre-vaccination titer above 0.1 IU/mL): an increase in antibody titer of at least 4 times the pre-vaccination titer</description>
          <population>Analysis was performed on the According to Protocol (ATP) cohort for immunogenicity Month 1, and only for Cervarix + Boostrix/Menactra, Cervarix + Boostrix + Menactra and Boostrix/Cervarix groups.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="199"/>
                <count group_id="O4" value="199"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-D (n=193,199,199)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="175"/>
                    <measurement group_id="O3" value="196"/>
                    <measurement group_id="O4" value="182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-T (n=194,199,199)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157"/>
                    <measurement group_id="O3" value="162"/>
                    <measurement group_id="O4" value="168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Booster Response for Anti-PT, Anti-FHA and Anti-PRN</title>
        <description>Booster responses defined as:
For initially seronegative subjects (pre-vaccination titer below cut-off: &lt; 5 EL.U/mL): antibody titers at least 4 times the cut-off,
For initially seropositive subjects with pre-vaccination titer above 5 EL.U/mL and &lt; 20 EL.U/mL: an increase in antibody titers of at least 4 times the pre-vaccination titer,
For initially seropositive subjects with pre-vaccination titer ≥ 20 EL.U/mL: an increase in antibody titers of at least two times the pre-vaccination titer</description>
        <time_frame>One month after vaccination with Boostrix</time_frame>
        <population>Analysis was performed on the According-to-Protocol (ATP) cohort for analysis of immunogenicity Month 1, and only for Cervarix + Boostrix/Menactra, Cervarix + Boostrix + Menactra and Boostrix + Cervarix groups.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix + Boostrix/Menactra Group</title>
            <description>Subjects received Cervarix and Boostrix at Month 0, Menactra and Cervarix at Month 1 and Cervarix alone at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix + Menactra/Boostrix Group</title>
            <description>Subjects received Menactra and Cervarix at Month 0, Boostrix and Cervarix at Month 1 and Cervarix alone at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Cervarix + Boostrix + Menactra Group</title>
            <description>Subjects received Boostrix, Menactra and Cervarix at Month 0 and Cervarix alone at Months 1 and 6.</description>
          </group>
          <group group_id="O4">
            <title>Boostrix/Cervarix Group</title>
            <description>Subjects received Boostrix at Month 0 and Cervarix at Months 1, 2 and 7.</description>
          </group>
          <group group_id="O5">
            <title>Menactra/Cervarix Group</title>
            <description>Subjects received Menactra at Month 0 and Cervarix at Months 1, 2 and 7.</description>
          </group>
          <group group_id="O6">
            <title>Cervarix Group</title>
            <description>Subjects received Cervarix at Months 0, 1 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Booster Response for Anti-PT, Anti-FHA and Anti-PRN</title>
          <description>Booster responses defined as:
For initially seronegative subjects (pre-vaccination titer below cut-off: &lt; 5 EL.U/mL): antibody titers at least 4 times the cut-off,
For initially seropositive subjects with pre-vaccination titer above 5 EL.U/mL and &lt; 20 EL.U/mL: an increase in antibody titers of at least 4 times the pre-vaccination titer,
For initially seropositive subjects with pre-vaccination titer ≥ 20 EL.U/mL: an increase in antibody titers of at least two times the pre-vaccination titer</description>
          <population>Analysis was performed on the According-to-Protocol (ATP) cohort for analysis of immunogenicity Month 1, and only for Cervarix + Boostrix/Menactra, Cervarix + Boostrix + Menactra and Boostrix + Cervarix groups.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="197"/>
                <count group_id="O4" value="198"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-PT (n=194,196,198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138"/>
                    <measurement group_id="O3" value="116"/>
                    <measurement group_id="O4" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-FHA (n=192,195,196)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="167"/>
                    <measurement group_id="O3" value="163"/>
                    <measurement group_id="O4" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PRN (n=193,197,198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="183"/>
                    <measurement group_id="O3" value="180"/>
                    <measurement group_id="O4" value="177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Anti-A, Anti-C, Anti-Y and Anti-W135 Vaccine Response</title>
        <description>Vaccine responses for anti-A, C, Y and W-135 defined as:
For initially seronegative subjects (pre-vaccination titer below cut-off of 8): antibody titers at least 4 times the cut-off (post vaccination titer ≥ 32)
For initially seropositive subjects (pre-vaccination titer above 8): antibody titers at least 4 times the pre-vaccination antibody titer</description>
        <time_frame>One month after vaccination with Menactra</time_frame>
        <population>Analysis was performed on the According-to-Protocol (ATP) cohort for analysis of immunogenicity Month 1, and only for Cervarix + Menactra/Boostrix, Cervarix + Boostrix + Menactra and Menactra/Cervarix groups</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix + Boostrix/Menactra Group</title>
            <description>Subjects received Cervarix and Boostrix at Month 0, Menactra and Cervarix at Month 1 and Cervarix alone at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix + Menactra/Boostrix Group</title>
            <description>Subjects received Menactra and Cervarix at Month 0, Boostrix and Cervarix at Month 1 and Cervarix alone at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Cervarix + Boostrix + Menactra Group</title>
            <description>Subjects received Boostrix, Menactra and Cervarix at Month 0 and Cervarix alone at Months 1 and 6.</description>
          </group>
          <group group_id="O4">
            <title>Boostrix/Cervarix Group</title>
            <description>Subjects received Boostrix at Month 0 and Cervarix at Months 1, 2 and 7.</description>
          </group>
          <group group_id="O5">
            <title>Menactra/Cervarix Group</title>
            <description>Subjects received Menactra at Month 0 and Cervarix at Months 1, 2 and 7.</description>
          </group>
          <group group_id="O6">
            <title>Cervarix Group</title>
            <description>Subjects received Cervarix at Months 0, 1 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Anti-A, Anti-C, Anti-Y and Anti-W135 Vaccine Response</title>
          <description>Vaccine responses for anti-A, C, Y and W-135 defined as:
For initially seronegative subjects (pre-vaccination titer below cut-off of 8): antibody titers at least 4 times the cut-off (post vaccination titer ≥ 32)
For initially seropositive subjects (pre-vaccination titer above 8): antibody titers at least 4 times the pre-vaccination antibody titer</description>
          <population>Analysis was performed on the According-to-Protocol (ATP) cohort for analysis of immunogenicity Month 1, and only for Cervarix + Menactra/Boostrix, Cervarix + Boostrix + Menactra and Menactra/Cervarix groups</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="185"/>
                <count group_id="O3" value="188"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="192"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-A (n=170,160,167)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="127"/>
                    <measurement group_id="O3" value="112"/>
                    <measurement group_id="O5" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-C (n=184,189,182)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="162"/>
                    <measurement group_id="O3" value="163"/>
                    <measurement group_id="O5" value="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Y (n=183,188,192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="169"/>
                    <measurement group_id="O3" value="166"/>
                    <measurement group_id="O5" value="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-W135 (n=185,187,187)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="176"/>
                    <measurement group_id="O3" value="183"/>
                    <measurement group_id="O5" value="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Solicited Local Symptoms</title>
        <description>Solicited local symptoms assessed include pain, redness and swelling.</description>
        <time_frame>During the 7-day period following each vaccination</time_frame>
        <population>Analysis was performed on the Total Vaccinated cohort including all vaccinated subjects receiving one dose at least</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix + Boostrix/Menactra Group</title>
            <description>Subjects received Cervarix and Boostrix at Month 0, Menactra and Cervarix at Month 1 and Cervarix alone at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix + Menactra/Boostrix Group</title>
            <description>Subjects received Menactra and Cervarix at Month 0, Boostrix and Cervarix at Month 1 and Cervarix alone at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Cervarix + Boostrix + Menactra Group</title>
            <description>Subjects received Boostrix, Menactra and Cervarix at Month 0 and Cervarix alone at Months 1 and 6.</description>
          </group>
          <group group_id="O4">
            <title>Boostrix/Cervarix Group</title>
            <description>Subjects received Boostrix at Month 0 and Cervarix at Months 1, 2 and 7.</description>
          </group>
          <group group_id="O5">
            <title>Menactra/Cervarix Group</title>
            <description>Subjects received Menactra at Month 0 and Cervarix at Months 1, 2 and 7.</description>
          </group>
          <group group_id="O6">
            <title>Cervarix Group</title>
            <description>Subjects received Cervarix at Months 0, 1 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Solicited Local Symptoms</title>
          <description>Solicited local symptoms assessed include pain, redness and swelling.</description>
          <population>Analysis was performed on the Total Vaccinated cohort including all vaccinated subjects receiving one dose at least</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="209"/>
                <count group_id="O2" value="208"/>
                <count group_id="O3" value="209"/>
                <count group_id="O4" value="211"/>
                <count group_id="O5" value="209"/>
                <count group_id="O6" value="210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="197"/>
                    <measurement group_id="O2" value="204"/>
                    <measurement group_id="O3" value="204"/>
                    <measurement group_id="O4" value="203"/>
                    <measurement group_id="O5" value="193"/>
                    <measurement group_id="O6" value="201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="93"/>
                    <measurement group_id="O3" value="103"/>
                    <measurement group_id="O4" value="103"/>
                    <measurement group_id="O5" value="99"/>
                    <measurement group_id="O6" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                    <measurement group_id="O2" value="90"/>
                    <measurement group_id="O3" value="102"/>
                    <measurement group_id="O4" value="100"/>
                    <measurement group_id="O5" value="74"/>
                    <measurement group_id="O6" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Solicited General Symptoms</title>
        <description>Solicited general symptoms assessed include Arthralgia, fatigue, fever, gastrointestinal, headache, myalgia, rash and urticaria</description>
        <time_frame>During the 7-day period following each vaccination</time_frame>
        <population>Analysis was performed on the Total Vaccinated cohort including all vaccinated subjects receiving one dose at least</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix + Boostrix/Menactra Group</title>
            <description>Subjects received Cervarix and Boostrix at Month 0, Menactra and Cervarix at Month 1 and Cervarix alone at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix + Menactra/Boostrix Group</title>
            <description>Subjects received Menactra and Cervarix at Month 0, Boostrix and Cervarix at Month 1 and Cervarix alone at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Cervarix + Boostrix + Menactra Group</title>
            <description>Subjects received Boostrix, Menactra and Cervarix at Month 0 and Cervarix alone at Months 1 and 6.</description>
          </group>
          <group group_id="O4">
            <title>Boostrix/Cervarix Group</title>
            <description>Subjects received Boostrix at Month 0 and Cervarix at Months 1, 2 and 7.</description>
          </group>
          <group group_id="O5">
            <title>Menactra/Cervarix Group</title>
            <description>Subjects received Menactra at Month 0 and Cervarix at Months 1, 2 and 7.</description>
          </group>
          <group group_id="O6">
            <title>Cervarix Group</title>
            <description>Subjects received Cervarix at Months 0, 1 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Solicited General Symptoms</title>
          <description>Solicited general symptoms assessed include Arthralgia, fatigue, fever, gastrointestinal, headache, myalgia, rash and urticaria</description>
          <population>Analysis was performed on the Total Vaccinated cohort including all vaccinated subjects receiving one dose at least</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="209"/>
                <count group_id="O2" value="208"/>
                <count group_id="O3" value="210"/>
                <count group_id="O4" value="211"/>
                <count group_id="O5" value="209"/>
                <count group_id="O6" value="210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="34"/>
                    <measurement group_id="O4" value="48"/>
                    <measurement group_id="O5" value="33"/>
                    <measurement group_id="O6" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="111"/>
                    <measurement group_id="O4" value="118"/>
                    <measurement group_id="O5" value="99"/>
                    <measurement group_id="O6" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="28"/>
                    <measurement group_id="O5" value="35"/>
                    <measurement group_id="O6" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="62"/>
                    <measurement group_id="O3" value="70"/>
                    <measurement group_id="O4" value="65"/>
                    <measurement group_id="O5" value="65"/>
                    <measurement group_id="O6" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107"/>
                    <measurement group_id="O2" value="118"/>
                    <measurement group_id="O3" value="124"/>
                    <measurement group_id="O4" value="133"/>
                    <measurement group_id="O5" value="122"/>
                    <measurement group_id="O6" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="89"/>
                    <measurement group_id="O3" value="101"/>
                    <measurement group_id="O4" value="96"/>
                    <measurement group_id="O5" value="66"/>
                    <measurement group_id="O6" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="15"/>
                    <measurement group_id="O5" value="13"/>
                    <measurement group_id="O6" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urticaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Unsolicited Adverse Events (AEs)</title>
        <description>Unsolicited adverse event = Any adverse event (AE) reported in addition to those solicited during the clinical study. Also any “solicited” symptom with onset outside the specified period of follow-up for solicited symptoms was reported as an unsolicited adverse event.</description>
        <time_frame>During the 30-day period following each vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cervarix + Boostrix/Menactra Group</title>
            <description>Subjects received Cervarix and Boostrix at Month 0, Menactra and Cervarix at Month 1 and Cervarix alone at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix + Menactra/Boostrix Group</title>
            <description>Subjects received Menactra and Cervarix at Month 0, Boostrix and Cervarix at Month 1 and Cervarix alone at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Cervarix + Boostrix + Menactra Group</title>
            <description>Subjects received Boostrix, Menactra and Cervarix at Month 0 and Cervarix alone at Months 1 and 6.</description>
          </group>
          <group group_id="O4">
            <title>Boostrix/Cervarix Group</title>
            <description>Subjects received Boostrix at Month 0 and Cervarix at Months 1, 2 and 7.</description>
          </group>
          <group group_id="O5">
            <title>Menactra/Cervarix Group</title>
            <description>Subjects received Menactra at Month 0 and Cervarix at Months 1, 2 and 7.</description>
          </group>
          <group group_id="O6">
            <title>Cervarix Group</title>
            <description>Subjects received Cervarix at Months 0, 1 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Unsolicited Adverse Events (AEs)</title>
          <description>Unsolicited adverse event = Any adverse event (AE) reported in addition to those solicited during the clinical study. Also any “solicited” symptom with onset outside the specified period of follow-up for solicited symptoms was reported as an unsolicited adverse event.</description>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
                <count group_id="O2" value="214"/>
                <count group_id="O3" value="214"/>
                <count group_id="O4" value="214"/>
                <count group_id="O5" value="214"/>
                <count group_id="O6" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108"/>
                    <measurement group_id="O2" value="121"/>
                    <measurement group_id="O3" value="119"/>
                    <measurement group_id="O4" value="122"/>
                    <measurement group_id="O5" value="127"/>
                    <measurement group_id="O6" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Serious Adverse Events</title>
        <description>Serious adverse events assessed include medical occurrences that results in death, is life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
        <time_frame>During the active phase of the study (up to Month 7 or Month 8) and throughout the entire study (up to Month 12 or Month 13)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cervarix + Boostrix/Menactra Group</title>
            <description>Subjects received Cervarix and Boostrix at Month 0, Menactra and Cervarix at Month 1 and Cervarix alone at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix + Menactra/Boostrix Group</title>
            <description>Subjects received Menactra and Cervarix at Month 0, Boostrix and Cervarix at Month 1 and Cervarix alone at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Cervarix + Boostrix + Menactra Group</title>
            <description>Subjects received Boostrix, Menactra and Cervarix at Month 0 and Cervarix alone at Months 1 and 6.</description>
          </group>
          <group group_id="O4">
            <title>Boostrix/Cervarix Group</title>
            <description>Subjects received Boostrix at Month 0 and Cervarix at Months 1, 2 and 7.</description>
          </group>
          <group group_id="O5">
            <title>Menactra/Cervarix Group</title>
            <description>Subjects received Menactra at Month 0 and Cervarix at Months 1, 2 and 7.</description>
          </group>
          <group group_id="O6">
            <title>Cervarix Group</title>
            <description>Subjects received Cervarix at Months 0, 1 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Serious Adverse Events</title>
          <description>Serious adverse events assessed include medical occurrences that results in death, is life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
                <count group_id="O2" value="214"/>
                <count group_id="O3" value="214"/>
                <count group_id="O4" value="214"/>
                <count group_id="O5" value="214"/>
                <count group_id="O6" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>During the active phase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>During the entire study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Unsolicited Adverse Events as New Onset Chronic Diseases (NOCDs)</title>
        <description>NOCDs assessed include e.g. autoimmune disorders, asthma, type I diabetes</description>
        <time_frame>During the active phase of the study (up to Month 7 or Month 8) and throughout the entire study period (up to Month 12 or Month 13)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cervarix + Boostrix/Menactra Group</title>
            <description>Subjects received Cervarix and Boostrix at Month 0, Menactra and Cervarix at Month 1 and Cervarix alone at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix + Menactra/Boostrix Group</title>
            <description>Subjects received Menactra and Cervarix at Month 0, Boostrix and Cervarix at Month 1 and Cervarix alone at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Cervarix + Boostrix + Menactra Group</title>
            <description>Subjects received Boostrix, Menactra and Cervarix at Month 0 and Cervarix alone at Months 1 and 6.</description>
          </group>
          <group group_id="O4">
            <title>Boostrix/Cervarix Group</title>
            <description>Subjects received Boostrix at Month 0 and Cervarix at Months 1, 2 and 7.</description>
          </group>
          <group group_id="O5">
            <title>Menactra/Cervarix Group</title>
            <description>Subjects received Menactra at Month 0 and Cervarix at Months 1, 2 and 7.</description>
          </group>
          <group group_id="O6">
            <title>Cervarix Group</title>
            <description>Subjects received Cervarix at Months 0, 1 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Unsolicited Adverse Events as New Onset Chronic Diseases (NOCDs)</title>
          <description>NOCDs assessed include e.g. autoimmune disorders, asthma, type I diabetes</description>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
                <count group_id="O2" value="214"/>
                <count group_id="O3" value="214"/>
                <count group_id="O4" value="214"/>
                <count group_id="O5" value="214"/>
                <count group_id="O6" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>During the active phase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>During the entire study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="12"/>
                    <measurement group_id="O6" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Medically Significant Adverse Events (AEs)</title>
        <description>Medically significant AEs assessed include AEs prompting emergency room or physician visits that are not related to common diseases or SAEs that are not related to common diseases.</description>
        <time_frame>During the active phase (up to Month 7 or Month 8) and throughout the entire study (up to Month 12 or Month 13)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cervarix + Boostrix/Menactra Group</title>
            <description>Subjects received Cervarix and Boostrix at Month 0, Menactra and Cervarix at Month 1 and Cervarix alone at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix + Menactra/Boostrix Group</title>
            <description>Subjects received Menactra and Cervarix at Month 0, Boostrix and Cervarix at Month 1 and Cervarix alone at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Cervarix + Boostrix + Menactra Group</title>
            <description>Subjects received Boostrix, Menactra and Cervarix at Month 0 and Cervarix alone at Months 1 and 6.</description>
          </group>
          <group group_id="O4">
            <title>Boostrix/Cervarix Group</title>
            <description>Subjects received Boostrix at Month 0 and Cervarix at Months 1, 2 and 7.</description>
          </group>
          <group group_id="O5">
            <title>Menactra/Cervarix Group</title>
            <description>Subjects received Menactra at Month 0 and Cervarix at Months 1, 2 and 7.</description>
          </group>
          <group group_id="O6">
            <title>Cervarix Group</title>
            <description>Subjects received Cervarix at Months 0, 1 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Medically Significant Adverse Events (AEs)</title>
          <description>Medically significant AEs assessed include AEs prompting emergency room or physician visits that are not related to common diseases or SAEs that are not related to common diseases.</description>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
                <count group_id="O2" value="214"/>
                <count group_id="O3" value="214"/>
                <count group_id="O4" value="214"/>
                <count group_id="O5" value="214"/>
                <count group_id="O6" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>During the active phase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="51"/>
                    <measurement group_id="O4" value="56"/>
                    <measurement group_id="O5" value="62"/>
                    <measurement group_id="O6" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>During the entire study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="54"/>
                    <measurement group_id="O4" value="59"/>
                    <measurement group_id="O5" value="64"/>
                    <measurement group_id="O6" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Cervarix + Boostrix/Menactra Group</title>
          <description>Subjects received Cervarix and Boostrix at Month 0, Menactra and Cervarix at Month 1 and Cervarix alone at Month 6.</description>
        </group>
        <group group_id="E2">
          <title>Cervarix + Menactra/Boostrix Group</title>
          <description>Subjects received Menactra and Cervarix at Month 0, Boostrix and Cervarix at Month 1 and Cervarix alone at Month 6.</description>
        </group>
        <group group_id="E3">
          <title>Cervarix + Boostrix + Menactra Group</title>
          <description>Subjects received Boostrix, Menactra and Cervarix at Month 0 and Cervarix alone at Months 1 and 6.</description>
        </group>
        <group group_id="E4">
          <title>Boostrix/Cervarix Group</title>
          <description>Subjects received Boostrix at Month 0 and Cervarix at Months 1, 2 and 7.</description>
        </group>
        <group group_id="E5">
          <title>Menactra/Cervarix Group</title>
          <description>Subjects received Menactra at Month 0 and Cervarix at Months 1, 2 and 7.</description>
        </group>
        <group group_id="E6">
          <title>Cervarix Group</title>
          <description>Subjects received Cervarix at Months 0, 1 and 6.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1"/>
                <counts group_id="E2" subjects_affected="3"/>
                <counts group_id="E3" subjects_affected="4"/>
                <counts group_id="E4" subjects_affected="0"/>
                <counts group_id="E5" subjects_affected="7"/>
                <counts group_id="E6" subjects_affected="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="215"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Hyphaema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="215"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Proctitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="215"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="215"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="215"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="215"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="215"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="215"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Facial palsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="215"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous complete</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="215"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Adjustment disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Conversion disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="215"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="215"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Stevens-johnson syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="215"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="197"/>
                <counts group_id="E2" subjects_affected="204"/>
                <counts group_id="E3" subjects_affected="204"/>
                <counts group_id="E4" subjects_affected="203"/>
                <counts group_id="E5" subjects_affected="193"/>
                <counts group_id="E6" subjects_affected="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="197" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="204" subjects_at_risk="208"/>
                <counts group_id="E3" subjects_affected="204" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="203" subjects_at_risk="211"/>
                <counts group_id="E5" subjects_affected="193" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="201" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <counts group_id="E1" subjects_affected="97" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="93" subjects_at_risk="208"/>
                <counts group_id="E3" subjects_affected="103" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="103" subjects_at_risk="211"/>
                <counts group_id="E5" subjects_affected="99" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="93" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="94" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="90" subjects_at_risk="208"/>
                <counts group_id="E3" subjects_affected="102" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="100" subjects_at_risk="211"/>
                <counts group_id="E5" subjects_affected="74" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="86" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="208"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="210"/>
                <counts group_id="E4" subjects_affected="48" subjects_at_risk="211"/>
                <counts group_id="E5" subjects_affected="33" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="47" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="94" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="100" subjects_at_risk="208"/>
                <counts group_id="E3" subjects_affected="111" subjects_at_risk="210"/>
                <counts group_id="E4" subjects_affected="118" subjects_at_risk="211"/>
                <counts group_id="E5" subjects_affected="99" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="98" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="208"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="210"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="211"/>
                <counts group_id="E5" subjects_affected="35" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="23" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="208"/>
                <counts group_id="E3" subjects_affected="70" subjects_at_risk="210"/>
                <counts group_id="E4" subjects_affected="65" subjects_at_risk="211"/>
                <counts group_id="E5" subjects_affected="65" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="69" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="107" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="118" subjects_at_risk="208"/>
                <counts group_id="E3" subjects_affected="124" subjects_at_risk="210"/>
                <counts group_id="E4" subjects_affected="133" subjects_at_risk="211"/>
                <counts group_id="E5" subjects_affected="122" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="112" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="89" subjects_at_risk="208"/>
                <counts group_id="E3" subjects_affected="101" subjects_at_risk="210"/>
                <counts group_id="E4" subjects_affected="96" subjects_at_risk="211"/>
                <counts group_id="E5" subjects_affected="66" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="89" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="208"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="210"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="211"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="208"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="210"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="211"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="209"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Injection site haematoma</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="31" subjects_at_risk="214"/>
                <counts group_id="E5" subjects_affected="22" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="17" subjects_at_risk="215"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharynigitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="214"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="18" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="214"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="215"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="214"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="18" subjects_at_risk="215"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="214"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="215"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="214"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="214"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="214"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="215"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

